RXi Changes Name, Plans to Spin out RNAi Operations into New Public Company | GenomeWeb

By Doug Macron

Just six months after transforming itself into a drug developer focused on both RNAi and cancer immunotherapies, RXi Pharmaceuticals said this week that it will spin out its activities with the gene-silencing technology into a new publicly traded company.

The new RNAi firm will retain the RXi name, while the other half of the company's operations, which will focus solely on the immunotherapy activities, will be conducted as Galena Biopharma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.